Table 4.
Laboratory parameters in MetS patients at baseline and post-fasting in two groups a
| Control group | Carnitine group | Δ P-value | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Post-fasting | P-valueb | Change | Baseline | Post-fasting | P-valueb | Change | ||
| FBG (mmol/L) | 5.1 ± 0.92 | 3.8 ± 0.86 | 0.007 | -1.3 ± 0.93 | 5.2 ± 0.61 | 4.2 ± 0.66 | 0.001 | -1.07 ± 0.76 | 0.066 |
| FINS (µU/mL) | 16.64 ± 4.98 | 10.32 ± 5.44 | <0.001 | -6.32 ± 3.44 | 17.87 ± 5.81 | 8.30 ± 4.05 | <0.001 | -9.9 ± 3.58 | 0.046 |
| HOMA-IR | 3.77 ± 1.35 | 1.74 ± 0.98 | <0.001 | -2.03 ± 1.33 | 4.13 ± 1.38 | 1.55 ± 0.87 | <0.001 | -2.78 ± 1.07 | 0.078 |
| HS-CRP (mg/L) | 2.3 ± 3.74 | 2.2 ± 3.22 | 0.716 | -0.04 ± 0.38 | 3.06 ± 1.69 | 2.7 ± 1.45 | 0.794 | -0.09 ± 1.64 | 0.991 |
| UA (umol/L) | 322.2 ± 93.92 | 527.6 ± 175.1 | <0.001 | 205.4 ± 167 | 329.3 ± 101.82 | 460.16 ± 161.33 | 0.003 | 130.8 ± 132.9 | 0.196 |
| FFA (umol/L) | 444.4 ± 120.3 | 990 ± 469.5 | 0.004 | 545.6 ± 450.3 | 454.0 ± 181.51 | 1187.9 ± 490.96 | 0.002 | 831.1 ± 573.9 | 0.076 |
| AST (U/L) | 22.2 ± 5.87 | 30.6 ± 15.7 | 0.014 | 8.39 ± 11.63 | 26.1 ± 7.74 | 33.9 ± 17.01 | 0.045 | 7.71 ± 12.99 | 0.883 |
| ALT (U/L) | 21.3 ± 11.98 | 31.3 ± 26.31 | 0.030 | 9.99 ± 15.96 | 25.7 ± 10.76 | 29.3 ± 14.13 | 0.112 | 5.5 ± 12.08 | 0.403 |
| γ-GGT (U/L) | 24.7 ± 10.7 | 22.3 ± 9.32 | 0.076 | -2.07 ± 4.18 | 30.2 ± 13.97 | 22.6 ± 8.62 | 0.002 | -7.07 ± 6.82 | 0.024 |
Abbreviation: γ-GGT γ-glutamyltransferase, AST Aspartate aminotransferase, ALT Alanine aminotransferase, FBP Fasting blood glucose, FINS Fasting insulin, HOMA-IR Homeostasis model assessment- Insulin Resistance, Hs-CRP Hypersensitivity C reaction protein, FFA free fatty acid, UA uric acid.
aVariables are expressed as mean ± SD.
b P-value was determined by paired test between baseline and post-fasting.
Δ P-value was determined by unpaired test between groups in difference.